ABAbdulkarim S. Binshaya

Abdulkarim S. Binshaya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Abdulkarim S. Binshaya has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Adil Abalkhail

    Department of Public Health College of Public Health and Health Informatics Qassim University Buraydah Qassim Saudi Arabia

    4 shared publications
  • Farhan R. Khan

    Department of Clinical Laboratory Sciences College of Applied Medical Sciences Al‐Quwayiyah Shaqra University Riyadh Saudi Arabia

    4 shared publications
  • Ali Hazazi

    Department of Pathology and Laboratory Medicine Security Forces Hospital Program Riyadh Saudi Arabia

    3 shared publications
  • Khalid Alshaghdali

    Department of Clinical Laboratory Sciences College of Applied Medical Sciences University of Hail Hail Saudi Arabia

    3 shared publications
  • Somia A. Nassar

    Department of Medical Laboratory Science, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia; Department of Parasitology & Animal Diseases, National Research Centre, 33 Bohouth St., Dokki, Giza 12622, Egypt

    3 shared publications
  • Fahad Almarshadi

    Department of Public Health, College of Public Health and Health Informatics, University of Ha'il, Saudi Arabia

    2 shared publications

Latest Publications

  • Phytochemical profiling and bioactivity evaluation of butanol Spartium junceum flower extract: GC-MS characterization, anticancer, antioxidant, antibiofilm, and anti-obesity potential with public health implications

    by Nada H. Aljarba, Munirah F. Aldayel, Adil Abalkhail, Abdulkarim S. Binshaya, Mohamed K. Y. Soliman

    The phytochemical composition and biological activities of Spartium junceum flower extracts were studied after fractionation using solvents of increasing polarity. Among the tested fractions, the butanol extract exhibited the highest levels of total phenolics, flavonoids, flavonols, and tannins, suggesting enrichment in polar bioactive metabolites. Gas chromatography-mass spectrometry (GC–MS) analysis revealed that the major constituents were mainly fatty acids and unsaturated lipid derivatives, including n-hexadecanoic acid, linoelaidic acid, oleic acid, and linoleic acid methyl ester. The butanol fraction demonstrated significant cytotoxic activity against MCF-7 breast and PC-3 prostate cancer cell lines, with IC₅₀ values of 96 and 89.8 µg/mL, respectively, while showing lower toxicity toward normal WI-38 cells. Moderate antioxidant activity was confirmed using (2,2-diphenyl-1-picryl-hydrazyl-hydrate), (2,2 (3-ethylbenzothiazoline-6-sulfonic acid) (ABTS), and total antioxidant capacity assays, with the strongest scavenging effect observed in the ABTS method. Additionally, the extract showed pancreatic lipase inhibitory potential (IC₅₀ = 79.6 µg/mL) and concentration-dependent antibiofilm activity against Staphylococcus aureus and Escherichia coli. These findings support S. junceum flowers as a promising source of multifunctional natural therapeutics.


  • Varicella‐zoster virus‐related neurological complications: From infection to immunomodulatory therapies

    by Mohammed Ageeli Hakami, Farhan R. Khan, Osama Abdulaziz, Khalid Alshaghdali, Ali Hazazi, Awad F. Aleissi, Adil Abalkhail, Bader S. Alotaibi, Abdulfattah Yahya M. Alhazmi, Neelima Kukreti, et al.

    The Varicella‐zoster virus (VZV), classified as a neurotropic member of the Herpesviridae family, exhibits a characteristic pathogenicity, predominantly inducing varicella, commonly known as chickenpox, during the initial infectious phase, and triggering the reactivation of herpes zoster, more commonly recognized as shingles, following its emergence from a latent state. The pathogenesis of VZV‐associated neuroinflammation involves a complex interplay between viral replication within sensory ganglia and immune‐mediated responses that contribute to tissue damage and dysfunction. Upon primary infection, VZV gains access to sensory ganglia, establishing latent infection within neurons. During reactivation, the virus can spread along sensory nerves, triggering a cascade of inflammatory mediators, chemokines, and immune cell infiltration in the affected neural tissues. The role of both adaptive and innate immune reactions, including the contributions of T and B cells, macrophages, and dendritic cells, in orchestrating the immune‐mediated damage in the central nervous system is elucidated. Furthermore, the aberrant activation of the natural defence mechanism, characterised by the dysregulated production of immunomodulatory proteins and chemokines, has been implicated in the pathogenesis of VZV‐induced neurological disorders, such as encephalitis, myelitis, and vasculopathy. The intricate balance between protective and detrimental immune responses in the context of VZV infection emphasises the necessity for an exhaustive comprehension of the immunopathogenic mechanisms propelling neuroinflammatory processes. Despite the availability of vaccines and antiviral therapies, VZV‐related neurological complications remain a significant concern, particularly in immunocompromised individuals and the elderly. Elucidating these mechanisms might facilitate the emergence of innovative immunomodulatory strategies and targeted therapies aimed at mitigating VZV‐induced neuroinflammatory damage and improving clinical outcomes. This comprehensive understanding enhances our grasp of viral pathogenesis and holds promise for pioneering therapeutic strategies designed to mitigate the neurological ramifications of VZV infections.


  • The emerging role of noncoding RNAs in the PI3K/AKT/mTOR signalling pathway in breast cancer

    by Mohammed H. Abu-Alghayth, Farhan R. Khan, Tareg M. Belali, Adil Abalkhail, Khalid Alshaghdali, Somia A. Nassar, Nasser Eissa Almoammar, Hassan H. Almasoudi, Khater Balatone G. Hessien, Munirah Saad Aldossari, et al.


  • From diagnosis to therapy: The transformative role of lncRNAs in eye cancer management

    by Ali Hazazi, Abdulmajid A. AlShehah, Farhan R. Khan, Mohammed Ageeli Hakami, Fahad Almarshadi, Adil Abalkhail, Somia A. Nassar, Hassan H. Almasoudi, Amer Al Ali, Mohammed H. Abu-Alghayth, et al.


  • PVT1 lncRNA in lung cancer: A key player in tumorigenesis and therapeutic opportunities

    by Mohammed Ageeli Hakami, Ali Hazazi, Farhan R. Khan, Osama Abdulaziz, Khalid Alshaghdali, Adil Abalkhail, Somia A. Nassar, Bashir Ibrahim A. Omar, Fahad Almarshadi, Gaurav Gupta, et al.